World's Best Scientists 2026 revealed!
Robert B. Livingston

Robert B. Livingston

D-Index & Metrics

Medicine

D-Index
94
Citations
45900
World Ranking
10287
National Ranking
5290

Robert B. Livingston publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert B. Livingston sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 371 publications — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert B. Livingston D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert B. Livingston sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert B. Livingston was affiliated with the University of Arizona in the United States. Their research primarily focused on medicine, with eight publications in this field. Key subfields included pulmonary and respiratory medicine, surgery, cancer research, radiology, nuclear medicine and imaging, as well as pathology and forensic medicine.

The main topics addressed in Livingston's research spanned various aspects of cancer and treatment studies, including:

  • Breast Cancer Treatment Studies
  • Radiomics and Machine Learning in Medical Imaging
  • Breast Lesions and Carcinomas
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Ear and Head Tumors

Frequent publication venues where Livingston's work appeared included:

  • UNC Libraries
  • Innovation in Aging
  • JAMA Oncology
  • JMIR Research Protocols
  • Communications Psychology

Notable recent papers featured the following:

  • "Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer," 2020, published in JAMA Oncology
  • "Supporting Individuals With Cognitive Impairment and Family Members in Rural Communities: Protocol for a Mixed Methods Digital Health Study," 2025, published in JMIR Research Protocols
  • "Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial," 2020, published by UNC Libraries
  • "Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)," 2021, published by UNC Libraries
  • "TECHNOLOGY PREFERENCES AMONG MILD COGNITIVE IMPAIRMENT (MCI) DYADS LIVING IN A MEMORY CARE DESERT," 2024, published in Innovation in Aging

Frequent co-authors collaborating with Livingston included:

  • Eric Cerino
  • Megan McCoy
  • Margarita Martinez
  • Thomasina J. Seaton
  • Michael J. McCarthy

Best Publications

  • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

    Timothy Winton;Robert Livingston;David H Johnson;James Rigas

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

    Andrew T. Turrisi;Kyungmann Kim;Ronald Blum;William T. Sause

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

    Karen Kelly;John Crowley;Paul A. Bunn;Cary A. Presant

  • Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

    Kathy S. Albain;Valerie W. Rusch;John J. Crowley;Thomas W. Rice

  • Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

    Kathy S. Albain;John J. Crowley;Michael LeBlanc;Robert B. Livingston

  • Estrogen Receptor as an Independent Prognostic Factor for Early Recurrence in Breast Cancer

    William A. Knight;William A. Knight;Robert B. Livingston;Ernest J. Gregory;William L. McGuire

  • Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer

    William T. Sause;Charles Scott;Samuel Taylor;David H Johnson

  • Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

    William Sause;Patricia Kolesar;Samuel Taylor;David H Johnson

  • Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing

    Janice L. Gabrilove;Charles S. Cleeland;Robert B. Livingston;Brenda Sarokhan

  • Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study

    Antoinette J. Wozniak;John J. Crowley;Stanley P. Balcerzak;Geoffrey R. Weiss

  • Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500

    Jeffrey B. Smerage;William E. Barlow;Gabriel N. Hortobagyi;Eric P. Winer

  • Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

    Mary L. Disis;Emanuel Calenoff;Graham McLaughlin;Ann E. Murphy

  • A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer

    Steven M. Keller;Sudeshna Adak;Henry Wagner;Arnold Herskovic

  • HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods

    Hadi Yaziji;Lynn C. Goldstein;Todd S. Barry;Robert Werling

  • Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: Long-term results of Southwest Oncology Group trial 9416 (Intergroup trial 0160)

    Valerie W. Rusch;Dorothy J. Giroux;Michael J. Kraut;John Crowley

  • Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

    K S Albain;J J Crowley;M LeBlanc;R B Livingston

Frequent Co-Authors

Kathy S. Albain
Kathy S. Albain Loyola University Chicago
John Crowley
John Crowley Washington University in St. Louis
William E. Barlow
William E. Barlow Fred Hutchinson Cancer Research Center
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Julie R. Gralow
Julie R. Gralow American Society of Clinical Oncology
Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
David R. Gandara
David R. Gandara University of California, Davis
James N. Ingle
James N. Ingle Mayo Clinic
Nancy E. Davidson
Nancy E. Davidson University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can open diverse healthcare career pathways beyond traditional medical school. Many students interested in medicine also consider becoming pharmacists. Accredited online pharmacist degree programs provide flexible options to earn advanced pharmacy qualifications with affordable tuition.

Another popular field is health information management. A him degree online prepares you to manage medical data, ensuring patient information is secure and accurate while meeting regulatory standards.

For those interested in administrative roles, a medical billing and coding certification online can lead to opportunities in hospitals, clinics, and insurance companies. This certification is essential for those aiming to handle patient records and healthcare reimbursement processes.

Nursing also remains in high demand. The most affordable online nurse practitioner programs make it possible to earn advanced nursing credentials while continuing to work. Nurse practitioners enjoy strong job prospects and the flexibility to specialize in various clinical areas.

These online degrees offer practical, accessible routes into well-paying healthcare roles—perfect for those seeking alternatives or complements to a traditional medical education in the USA.

Best Scientists Citing Robert B. Livingston

Recently Published Articles